NOGO-a neutralising immunoglobulin for treatment of neurological diseases

1. An isolated antibody or functional fragment thereof which binds with and neutralises human NOGO-A wherein said antibody or functional fragment thereof comprises each of the following CDRs:

CDRL1 as set forth in SEQ ID NO: 1;

CDRL2 as set forth in SEQ ID NO: 2;

CDRL3 as set forth in SEQ ID NO: 3;

CDRH1 as set forth in SEQ ID NO: 4;

CDRH2 as set forth in SEQ ID NO: 5; and

CDRH3 as set forth in SEQ ID NO: 6 or an analog of CDRH3 wherein the amino acid sequence of CDRH3 is modified by one amino acid.

2. An isolated antibody according to claim 1 which binds to SEQ ID NO: 87.

3. An isolated antibody according to claim 1 wherein CDRH3 is as set forth in SEQ ID NO: 6.

4. An isolated antibody of claim 1 which is a monoclonal antibody.

5. An isolated antibody of claim 1 which is a humanised or chimeric antibody.

6. An isolated antibody according to claim 1 wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 37.

7. An isolated antibody according to claim 1 wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40.

8. A pharmaceutical composition comprising an isolated anti-NOGO antibody or functional fragment thereof according to claim 1 together with a pharmaceutically acceptable diluent or carrier.

9. The method of treatment or prophylaxis of stroke and other neurological diseases/disorders in a human which comprises administering to said human in need thereof an effective amount of an anti-NOGO antibody, according to claim 1 , including altered antibodies or a functional fragment thereof.

10. An isolated functional fragment of the antibody according to claim 1 which binds to SEQ ID NO: 87.

11. An isolated functional fragment of the antibody according to claim 1 .

12. An isolated functional fragment of the antibody according to claim 3 .